Drug intelligence / Profile preview

GSK1440115

Development stage: Phase 1
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

GSK1440115 is an orally active, small molecule antagonist of the urotensin II receptor (UTS2R/UT receptor), developed by GSK for the treatment of asthma. It acts as a competitive and selective inhibitor of the UT receptor, which is implicated in respiratory physiology and has been studied as a therapeutic target in asthma. Clinical studies have shown that GSK1440115 was safe and well-tolerated in both healthy subjects and asthmatic patients; however, no significant bronchodilator effect or improvement in lung function endpoints was observed. The drug reached Phase I clinical trials but there have been no recent reports of further development[1][2][3][4][5].

Other names: 1003878-16-7UNII-GCT6G5G3C7UNII-GCT-6G5G3C7UNII-GCT 6G5G3C7

Targets

UT (Urotensin-2 receptor)

Beyond the preview

Go deeper on GSK1440115.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK1440115.

Explore the full profile